GLP-1 Denied? How to Appeal Ozempic, Mounjaro, Wegovy and Zepbound Denials
If your insurance just said no to Ozempic, Mounjaro, Wegovy or Zepbound, you are not alone, and it is not the end of the road. A denial is often a paperwork problem, not a final answer.
My office now spends hours every week fighting GLP-1 denials. It is slow work. But when a patient finally gets the medication, loses weight, and sees their blood sugar and blood pressure improve, it is worth it. So many patients ask me the same questions that I made this guide. It covers why denials happen, what the new Medicare GLP-1 Bridge covers, and what you and your doctor can do about it.
Watch Dr. Kundlas explain GLP-1 denials and how to appeal:
Why GLP-1 Denials Happen
The first question is simple: why did your doctor prescribe the drug? The answer decides which set of rules applies to you.
| Your reason for the medication | Usual drugs | Who pays and how |
|---|---|---|
| Metabolic health: type 2 diabetes, obstructive sleep apnea, fatty liver disease (MASH, formerly NASH), heart risk | Ozempic, Mounjaro, Wegovy, Zepbound (depends on the FDA-approved use) | Your regular insurance or Medicare Part D plan, with prior authorization |
| Weight loss only | Wegovy, Zepbound, Foundayo | Medicare: the GLP-1 Bridge. Commercial plans: only if your plan or employer covers weight-loss drugs |
Insurance companies deny these drugs for three main reasons. The paperwork does not show an approved reason (for example, no A1C on file for diabetes, or no sleep study for sleep apnea). The drug is prescribed for a use the plan does not cover. Or your employer’s contract leaves the drug out entirely.
Find your row in the table first. Everything else follows from it.
How Big Is the Problem?
About 4 in 10 American adults live with obesity, and about 38 million Americans have diabetes (CDC). Now add the price. At list price these drugs cost roughly $1,000 to $1,350 a month (GLP-1 Watchdog, 2026).
Multiply those two numbers and you can see why insurers ration. They want the drug going to the right patient for the right reason, with the right paperwork. That is frustrating when you are the patient waiting. It also means a denial is usually about documentation, and documentation can be fixed.
The Medicare GLP-1 Bridge Program
For years, Medicare could not pay for a GLP-1 used only for weight loss. People on Medicare, Medicaid and TRICARE also cannot use drug-company coupons. The Medicare GLP-1 Bridge fills that gap. It runs from July 1, 2026 through December 31, 2027, and eligible patients pay about $50 a month (CMS; NCOA, 2026).
The Bridge covers weight loss only, and only Wegovy, Zepbound (KwikPen) and Foundayo. If you have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease, you go through your regular Part D plan instead.
| Tier | BMI | Also needed |
|---|---|---|
| 1 | 35+ | Nothing else |
| 2 | 30+ | Heart failure with preserved ejection fraction, uncontrolled high blood pressure despite two medicines, or chronic kidney disease stage 3a or worse |
| 3 | 27+ | Prediabetes, a past heart attack, a past stroke, or symptomatic peripheral artery disease |
Source: BCBS Michigan provider FAQ, June 2026, matching the CMS criteria.
Your doctor also has to confirm that you received counseling on diet and exercise. The Bridge expects you to do your part, not just take the shot. If you already started a GLP-1 before July 2026, your BMI at the time you started is the one that counts.
Regular Insurance and Employer Exclusions
If you are taking a GLP-1 for a metabolic condition, your plan will look for proof of an FDA-approved use. Today these drugs are approved, depending on the product, for type 2 diabetes, obstructive sleep apnea, fatty liver disease, and lowering the risk of heart attack and stroke. They also help protect the kidneys. They work at the root of the problem: they quiet food cravings, bring weight down, and improve insulin resistance.
If the plan thinks the drug was written for something outside those approved uses, it will deny it.
There is one denial that has nothing to do with your health. Your employer may have excluded GLP-1s from your benefits. You can have an insurance card, the right diagnosis and a doctor’s letter, and still be denied because of a contract between your employer and the insurer. That is a policy decision, so an appeal often cannot change it. Ask your HR department what your plan covers.
What to Do When You Get a Denial
A denial is the start of a process. Many denials get overturned once the right evidence is sent. In a KFF analysis, 43% of appealed denials were reversed in ACA marketplace plans and 67% in Medicare Advantage (summary of KFF data, 2026). Those numbers cover all kinds of care, not just GLP-1s, and success drops once a case reaches a second-level review in Medicare Part D (Klebanoff et al., Diabetes, Obesity and Metabolism, 2026). The lesson: get it right at the first appeal.
- Never accept a denial over the phone. Ask for it in writing, with the exact reason. That letter is the foundation of everything that follows.
- Match the reason to your indication. Weight loss on Medicare? Check your Bridge tier. Diabetes? You need your A1C and related lab work in the chart. Sleep apnea? You need a documented sleep study. Fatty liver? You need imaging or lab evidence.
- Ask your doctor for a letter of medical necessity. It should list your diagnoses, the test results that prove them, and why this drug fits you.
- File the appeal before the deadline. The deadline is printed on your denial letter. It is about two months for Medicare drug plans and up to six months for many private plans. Read it the day it arrives.
- Let your doctor request a peer-to-peer call if needed. Your physician speaks directly with the insurer’s medical director. I do several of these a day, often after 10 to 15 minutes on hold. A complete appeal packet makes that call shorter and more likely to succeed.
- For the Medicare GLP-1 Bridge, resubmit instead of appealing. A Bridge decision comes within about 72 hours. If it is denied, your doctor can correct the form and send it again (CMS pharmacy guide).
If You Still Don’t Qualify: Direct Purchase
If you do not meet the criteria, or your employer excludes these drugs, both makers now sell directly to patients at a lower cash price.
| Program | Drug | Self-pay price (2026) |
|---|---|---|
| LillyDirect | Zepbound | $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg) per month |
| NovoCare Pharmacy | Wegovy | About $299–$349 per month, depending on dose and form |
Sources: Healthcount, July 2026; Metabolic Ledger, May 2026. Prices change often, so check lillydirect.com or novocare.com before you order.
Watch the fine print. The starting dose is the cheapest, and the price climbs as your dose goes up. Cash purchases also do not count toward your insurance deductible.
Frequently Asked Questions
Why was my Ozempic or Mounjaro denied if I have diabetes?
Usually the paperwork is missing proof. Your plan wants to see your diagnosis and recent A1C in the chart. Ask for the written denial reason, then have your doctor send the missing records.
Can I get Wegovy or Zepbound through Medicare just for weight loss?
Yes, through the Medicare GLP-1 Bridge, if you have Part D coverage and meet one of the three BMI tiers. The copay is about $50 a month through December 31, 2027.
My Bridge request was denied. Can I appeal?
The Bridge does not use the usual appeal path. Your doctor can fix the form and resubmit it to the central processor for another review.
What if my employer excludes GLP-1 drugs?
An appeal rarely changes an employer exclusion because it is a contract decision. Talk to HR, ask whether a covered medical use applies to you, or look at the direct-purchase programs.
Should I take no for an answer on the phone?
No. Always ask for the denial in writing with the specific reason. Without it, you cannot build an appeal.
The Bottom Line
Know why you are taking the drug, know what your plan or the Bridge requires, and get every denial in writing. With that in hand, most patients can find their way through the maze. I have a full playlist on GLP-1 medications on the Kundlas MD channel if you want to go deeper.
At Shield Medical Group in Sebring and Lake Wales, Florida, we handle GLP-1 prior authorizations and appeals every day.
Educational only; talk to your clinician about your own situation.
Take care of your health. Take care of each other. I’ll see you in the next one.
Sources
- CMS: Medicare GLP-1 Bridge
- CMS: Information for Providers
- CMS: Bridge guide for pharmacies
- BCBS Michigan: Bridge provider FAQ, June 2026
- NCOA: Medicare GLP-1 Bridge, 2026
- Klebanoff et al.: Part D appeals for denied GLP-1 claims, 2026
- KFF appeal reversal data (summary), 2026
- Healthcount: GLP-1 prices, July 2026
